MedGenome Labs Brings clonoSEQ Assay in India
![The test identifies dominant immune cell clones at the time of high disease burden that can be monitored after the treatment to determine MRD.](https://healthwire.co/wp-content/uploads/2022/07/medgenome.jpg)
clonoSEQ is the 1st U. S. Food and Drug Administration (FDA) cleared MRD test for Multiple Myeloma, Chronic Lymphoblastic Leukaemia (CLL), and B-Acute Lymphoblastic Leukaemia (B-ALL). clonoSEQ is a highly sensitive NGS based assay which is increasingly becoming the standard practices in patient management.
Share